Recent Press Releases

BeneVir Biopharm, Inc. Announces Investment From HC2's Subsidiary Pansend, LLC

ROCKVILLE, MD--(Marketwired - Nov 21, 2014) - BeneVir Biopharm, Inc., a biotechnology company developing a pipeline of cancer immunotherapies, today announced it closed a Series A investment round...

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Study Met All Primary Endpoints Against...

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma

RARITAN, N.J., Nov. 24, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food and Drug...

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema CAMBRIDGE, Mass.--(BUSINESS...

Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO

Minerva Neurosciences, Inc. NERV, +4.52% today announced the appointment of Remy Luthringer, Ph.D., president and chief scientific officer of Minerva, to the additional post of chief executive...

Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589

Basel, November 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (NDA)...

Antiangiogenic treatment improves survival in animal model of ovarian cancer

Treatment with 3TSR regresses tumors, improves effectiveness of chemotherapy BOSTON -- Epithelial ovarian cancer is the most lethal cancer of the female reproductive organs, with more than 200,000...

Cell Medica announces £50 million Series B round to advance cancer program

Closing of a £50 million Series B investment round is announced with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management. London, UK – 25...

Imperial Innovations leads £50 million Series B funding round in Cell Medica

Imperial Innovations (AIM: IVO, "Innovations" or "The Group") has led a £50m series B funding round in Cell Medica ("Cell Medica" or "the Company") alongside co-investors Invesco Asset...

Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 24, 2014

Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types

NEW YORK and SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 (GLOBE NEWSWIRE) --Bristol-Myers Squibb Company (BMY) and Five Prime Therapeutics, Inc. (FPRX) today announced that they have entered into an...

Lexicon Announces Pricing Of Common Stock Offering

THE WOODLANDS, Texas, Nov. 21, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. LXRX, +4.23% today announced the pricing of its previously announced underwritten public offering of $50,000,000 of...

Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and...

Ulf Wiinberg resigns as CEO of Lundbeck

Valby, Copenhagen, 2014-11-24 08:56 CET (GLOBE NEWSWIRE) -- Ulf Wiinberg has informed Lundbeck's Board of Directors that he is resigning as Chief Executive Officer with immediate effect The...

Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation

SEATTLE, Nov. 24, 2014 /PRNewswire/ -- Juno Therapeutics today announced that the FDA has granted Breakthrough Therapy Designation to the company's JCAR015 chimeric antigen receptor product...

Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine

Clinical Development, Manufacturing Expertise, and Scale Critical to Success Business Wire Merck  Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational...

BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD) Drisapersen is currently...

STALLERGENES And ActoGenix To Develop An Innovative New Class Of Oral Allergy Treatments

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX's technology for targeted delivery of allergen-based treatments ANTONY, France and GHENT, Belgium,...